A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses
Not Applicable
Completed
- Conditions
- Cataract
- Registration Number
- NCT01299155
- Lead Sponsor
- Alcon Research
- Brief Summary
To prospectively evaluate postoperative visual and refractive parameters in a series of subjects bilaterally implanted with AcrySof ReSTOR +3 vs. those bilaterally implanted with LENTIS MPlus Intraocular Lens (IOL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- are willing and able to understand and sign an informed consent
- <= 1.0 Diopters of regular corneal astigmatism in both eyes. NOTE: look for consistency between manual keratometry, auto-keratometry and simulated keratometry measures to ensure "regular" astigmatism prior to enrollment. Subjects who wear contact lenses must discontinue its use for at least 2 weeks (soft contact lens) and at least 3 weeks (gas permeable contact lens) and until corneal topography shows stability prior to preoperative study measurements.
- are willing and able to attend postoperative examinations per protocol schedule
- are more than 21 years of age, of either gender and any race:
- require bilateral cataract extraction followed by posterior intraocular lens (IOL) implantation used as on-label procedure
- be willing to have second eye surgery within one month of first eye surgery
- are in good ocular health, with the exception of cataracts
- are free of disease(s)/condition(s) listed in the "Precautions" section of the AcrySof IQ ReSTOR +3 and LENTIS Mplus package inserts
- are able to read and understand one of the following languages: Dutch or Spanish
Exclusion Criteria
- Planned multiple procedures, including limbal relaxing incision (LRI), during cataract/IOL implantation surgery
- An ocular disease and/or condition that may compromise visual acuity levels (i.e. glaucoma, diabetic retinopathy, macular degeneration, amblyopia, pupil abnormality such as corectopia, etc.)
- Previous corneal surgery and/or reshaping
- Clinically significant corneal endothelial dystrophy (e.g. Fuchs' dystrophy)
- History of corneal disease (eg. herpes simplex, herpes zoster keratitis, etc.)
- History of retinal detachment
- Subjects that have an acute or chronic disease or illness that would increase the operative risk or confound the results of this investigation (eg, immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness).
- suturing of incision required at time of surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Unilateral Uncorrected Near Visual Acuity 3 months after surgery
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which ReSTOR +3 and LENTIS MPlus IOLs correct presbyopia in cataract patients?
How does the efficacy of ReSTOR +3 and LENTIS MPlus IOLs compare to standard monofocal lenses in cataract surgery?
What biomarkers are associated with improved visual outcomes following implantation of presbyopia-correcting IOLs in cataract patients?
What are the potential adverse events and management strategies for bilateral implantation of ReSTOR +3 and LENTIS MPlus IOLs in cataract patients?
Are there combination approaches or competitor devices that enhance presbyopia correction when used alongside ReSTOR +3 or LENTIS MPlus IOLs in cataract treatment?
Trial Locations
- Locations (1)
Contact Alcon Call Center for Trial Locations
🇪🇸Oviedo, Asturias, Spain
Contact Alcon Call Center for Trial Locations🇪🇸Oviedo, Asturias, Spain